Knoll Capital Management 13F annual report

Knoll Capital Management is an investment fund managing more than $96.3 billion ran by Fred Knoll. There are currently 37 companies in Mr. Knoll’s portfolio. The largest investments include Aldeyra Therapeutics Inc and Applied Therapeutics, together worth $33.1 billion.

Limited to 30 biggest holdings

$96.3 billion Assets Under Management (AUM)

As of 7th November 2023, Knoll Capital Management’s top holding is 3,031,915 shares of Aldeyra Therapeutics Inc currently worth over $20.3 billion and making up 21.0% of the portfolio value. Relative to the number of outstanding shares of Aldeyra Therapeutics Inc, Knoll Capital Management owns less than approximately 0.1% of the company. In addition, the fund holds 5,162,088 shares of Applied Therapeutics worth $12.9 billion, whose value fell approximately 0.1% in the past six months. The third-largest holding is Biohaven Pharmactl Hldg Co L worth $12.8 billion and the next is Avadel Pharmaceuticals plc worth $6.18 billion, with 600,000 shares owned.

Currently, Knoll Capital Management's portfolio is worth at least $96.3 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Knoll Capital Management

The Knoll Capital Management office and employees reside in Miami, Florida. According to the last 13-F report filed with the SEC, Fred Knoll serves as the President at Knoll Capital Management.

Recent trades

In the most recent 13F filing, Knoll Capital Management revealed that it had opened a new position in Kinross Gold and bought 440,000 shares worth $2.01 billion. This means they effectively own approximately 0.1% of the company. Kinross Gold makes up 12.2% of the fund's Materials sector allocation and has grown its share price by 22.0% in the past year.

The investment fund also strengthened its position in Aldeyra Therapeutics Inc by buying 16,247 additional shares. This makes their stake in Aldeyra Therapeutics Inc total 3,031,915 shares worth $20.3 billion. Aldeyra Therapeutics Inc dropped 56.4% in the past year.

On the other hand, there are companies that Knoll Capital Management is getting rid of from its portfolio. Knoll Capital Management closed its position in Altimmune Inc on 14th November 2023. It sold the previously owned 173,864 shares for $614 million. Fred Knoll also disclosed a decreased stake in Ocular Therapeutix Inc by 1.0%. This leaves the value of the investment at $1.26 million and 400 shares.

One of the smallest hedge funds

The two most similar investment funds to Knoll Capital Management are Wfa Of San Diego and Paragon Financial Partners, Inc. They manage $96.4 billion and $96.3 billion respectively.


Fred Knoll investment strategy

Knoll Capital Management’s portfolio is diversified across 6 sectors. Currently, their heaviest sector is Health Care — making up 48.0% of the total portfolio value. The fund focuses on investments in the United States as 32.4% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up 19% of the total holdings value. On the other hand, small-cap stocks make up 13.5% of the portfolio. The average market cap of the portfolio companies is close to $38.9 billion.

The complete list of Knoll Capital Management trades based on 13F SEC filings

These positions were updated on November 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security Shares Owned Value Allocation
Aldeyra Therapeutics Inc
0.54%
3,031,915
$20,253,192,000 21.02%
Applied Therapeutics, Inc.
49.63%
5,162,088
$12,853,599,000 13.34%
Biohaven Pharmactl Hldg Co L
8.88%
490,422
$12,755,876,000 13.24%
Avadel Pharmaceuticals plc
20.00%
600,000
$6,180,000,000 6.41%
Hookipa Pharma Inc
No change
5,517,385
$3,398,709,000 3.53%
Verona Pharma
No change
200,000
$3,260,000,000 3.38%
Seabridge Gold, Inc.
208.25%
246,597
$2,601,598,000 2.70%
Vaneck Gold Miners Etf
No change
91,850
$2,471,683,000 2.57%
Global X Silver Miners Etf 37954y848
No change
89,700
$2,143,830,000 2.23%
Kinross Gold Corp.
Opened
440,000
$2,006,400,000 2.08%
Franco Nev Corp Cad
107.14%
14,500
$1,935,605,000 2.01%
Wheaton Precious Metals Corp
Opened
47,500
$1,926,125,000 2.00%
Agnico Eagle Mines Ltd
Opened
40,000
$1,818,000,000 1.89%
Silvercrest Metals Inc Cad
141.18%
410,000
$1,808,100,000 1.88%
Entera Bio Ltd
No change
2,484,275
$1,801,099,000 1.87%
Equinox Gold Corp
Opened
420,929
$1,780,529,000 1.85%
Vaneck Junior Gold Miners Etf
No change
53,150
$1,713,024,000 1.78%
MAG Silver Corp.
Opened
160,000
$1,659,200,000 1.72%
Booz Allen Hamilton Hldg Cor
No change
13,000
$1,420,510,000 1.47%
First Majestic Silver Corporation
Opened
275,000
$1,410,750,000 1.46%
Visa Inc
No change
4,850
$1,115,548,000 1.16%
Thermo Fischer Scientific Inc
No change
2,100
$1,062,957,000 1.10%
CVS Health Corp
No change
14,500
$1,012,390,000 1.05%
Altria Group Inc.
No change
22,700
$954,535,000 0.99%
Northrop Grumman Corp.
No change
2,165
$953,011,000 0.99%
Alamos Gold Inc.
Opened
80,000
$903,200,000 0.94%
Lockheed Martin Corp.
Opened
2,150
$879,264,000 0.91%
Royal Gold, Inc.
Opened
7,550
$802,791,000 0.83%
Pan American Silver Corp
Opened
54,085
$783,150,000 0.81%
Osisko Gold Royalties Ltd
No change
400,000
$732,000,000 0.76%
Altimmune Inc
Closed
173,864
$613,739,000
Amylyx
Opened
24,772
$453,575,000 0.47%
Orgenesis Inc
No change
634,738
$393,537,000 0.41%
Omega Therapeutics Inc.
No change
173,010
$371,971,000 0.39%
Ocuphire Pharma, Inc.
No change
100,000
$335,000,000 0.35%
New Pac Metals Corp
Opened
131,654
$233,027,000 0.24%
Bioxcell
100.00%
60,000
$151,800,000 0.16%
Ocular Therapeutix Inc
99.80%
400
$1,256,000 0.00%
No transactions found
Showing first 500 out of 38 holdings